Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Taiwan Advance Bio-Pharmaceutical Inc.)
- Development stage
- Unknown
- Lead developer
- Taiwan Bio Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intrathecal, Intravenous
01
Overview
This autologous cell therapy, developed by Taiwan Advance Bio-Pharmaceutical, utilizes mesenchymal stem cells (MSCs) derived from a patient's own bone marrow. The cells are isolated, expanded in Good Tissue Practice (GTP)-certified facilities, and re-administered to the patient to promote tissue repair, regeneration, and immunomodulation. Operating under Taiwan's Special Management Regulations for cell therapy, this treatment is applied across diverse indications, including spinal cord injury, degenerative arthritis, knee cartilage defects, chronic ischemic stroke, and stage 4 solid tumors. The company collaborates with several major Taiwanese medical institutions, such as Lin Kou Chang Gung Memorial Hospital and Dalin Tzu Chi Hospital, to provide these therapeutic services as a clinical application rather than a traditional investigational drug.
- Other names
- autologous mesenchymal stem cellsBM-MSCsautologous bone marrow-derived mesenchymal stem cells-Taiwan Advance Bio-Pharmaceutical-cell therapy-autologous mesenchymal stem cells-spinal cord injury-degenerative arthritis-knee cartilage defects-stage 4 solid tumors-chronic ischemic stroke
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Taiwan Advance Bio-Pharmaceutical Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Taiwan Advance Bio-Pharmaceutical Inc.).